ALKERMES EXHIBIT 2003
`Apotex Inc. v. Alkermes Pharma Ireland Limited
`IPR2025-00514
`
`Page 1 of 4
`
`

`

`PTOVSR/S? (11-23)
`Approved for use through 11/30/2024. OMB 0551-0064
`
`US. DEPARTMENT OF COMMERCE
`U.S. Patent and Trademark Office;
`
`
`14.
`
`A copy of every patent ar printed publication relied upon is submitted herewith including a listing thereof on
`Form PTO/SB/08, PTO-1449, or equivalent.
`
`12. a An English language transiation of all necessary and pertinent non-English language patents and/or printed
`publications is attached.
`
`13.
`
`The atlached detailed request includes at least the following items:
`
`a. Astatement identifying each substantial new question of patentability based on oror patents and printed
`publications. 37 CFR 1.510(bi(1).
`
`An identification of every claim far which reexamination is requested, end a detailed explanation of the
`pertinency end manner of applying the cited art fo every claim for which reexamination is requested
`7 CFRIS1O(b2).
`
`414i| A proposed amendment is included (only where the patent owneris the requester). 37 CFR 1.570().
`
`415.
`
`itis certified that the statutory estoppel provisions of 35 U.S.C. 315(e}(1} or 35 USC. 325{e}(1) do not
`orchibit requester from filling this ex parte reexamination request. 37 CFR 1.570(a\(5).
`
`16.
`
`Servic
`
`a.
`
`tis certified that a copy of this request Cf fled by other than the patent owner) has been served in its
`entirety on the patent owner as provided in 37 CFR 1.33{c).
`
`ff applicable, femns a. ~c. are required.
`a. a Computer Readable Farm (CRF}
`b. Specification Sequence Listing on:
`i. a CD-ROM (2 capies) or CD-R (2 copies) ar
`ii. [| paper
`Cc. P| Statements verifying identity of above copies.
`9. [| A copy of any disclaimer, certificate of correction or reexarnination certificate issued in the patentis induded.
`5
`nati
`Salaimiay Tn 13
`i
`7
`
`10.1BB Reexamination of claim(s} is requested
`
`Under the Paperwark Reduction Aci of 1995, no persons are required to respondto a collection of information unless ii displays a valid OME control number. Nucleatide and/or Amino Acid Sequence Submission
`
`The name and address of the parly served are:
`Elmore Patent Law Group
`
`{Page 2 of 3}
`
`Page 2 of 4
`
`Page 2 of 4
`
`

`

`PTCVSB/S7 (11-23)
`Approved for use through 11/30/2024, OMB 0851-0064
`US. Patent and Trademark Office US. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required ta respond to a collection of information unless ii displays a valid OMB control number.
`
`Correspondence Address: Direct all communication about the reexamination to:
`
`The address associated with Customer Number: 239 4 4
`
`Firm or individual Name
`(al the address identified below)
`
`OR
`
`Address
`
`City
`
`Country
`
`For Third Party Requester
`
`18. a The patent is currently the subiect of the following concurrent proceeding(s):
`a. [I Copending reissue Application No.
`bo. a Copending reexamination Contra No.
`c. [| Capending Interference No.
`a ia Copending litigation styled:
`
`WARNING : Information on this form may become public. Credit card information should not be included on this
`form. Provide credit card information and authorization on PTO-2638.
`
`Shannon M. Leniz/
`
`42/16/2024
`
`Authorized Signature
`
`shannon M. Lentz
`
`Typed/Printed Name
`
`P| For Patent Owner Requester
`
`Regisiration No.
`
`jPage 3 of 3]
`
`Page 3 of 4
`
`Page 3 of 4
`
`

`

`Privacy Act Statement
`
`The Privacy Act of 1974 (F.L. 93-579} requires that you be given certain information in connection with your submission
`of the attached form related to a patent application or patent. The Unitec States Patent and Trademark Office (USPTO)
`collects the information in ihis record under authority of 35 U.S.C. 2. The USPTO's sysiem of recards is used to
`manage all applicant and owner information including name, citizenship, residence, post office address, and other
`information with respect to inventors and thei legal representatives pertaining to the applicant’s/owner’s activities in
`connection with the invention for which a patent is sought or has been granted. The applicable Privacy Act Systemof
`Records Notice for the inforrnation collected in this form is COMMERCE/PAT-TM-7 Patent Application Files, available in
`the Federal Register at 78 FR 19243 (March 29, 2013). https: /Mwww. govinfo.gov/content/pkg/F R-2013-03-29/
`pdi/2013-07341 pdf
`
`Routine uses of ihe information in this record may include disclosure to:
`
`Vj) jaw enforcement, in the event that the system of recorcs indicates a violation or potential violation of law;
`
`2) a federal, state, local, or international agency, in response to its request;
`
`3) a contractor of the USPTO having need for the information in order ta perform a contract:
`
`4) the Department of Justice for determination of whether the Freedomof information Act (FOIA) requires disclosure of
`the record,
`
`:
`5} a Member of Congress submitting a request involving an individual fo whomthe record pertains, when the individual
`has requested the Member's assistance with respect to the subject matter of the record:
`
`6) a court, magistrate, or administrative tribunal, in the course of presenting evidence, including disclosures to opposing
`counsel in the course of settlement negotiations:
`
`7) the Administrator, General Services Administration (GSA), or their designee, during an inspection of recards
`conducted by GSA under authority of 44 U.S.C. 2904 and 2306, in accordance with the GSA regulations and any other
`relevant (Le., GSA ar Commerce) directive, where such disclosure shall not bs usec to make determinations about
`individuals:
`
`8) another federal agency for purposes of Nationa! Security review (35 U.S.C. 184) and for review pursuant to the
`Atomic Energy Act (42 U.S.C. 218ic)).
`
`}
`\
`f
`9) the Office of Personnel Managament (OPM) for personnel reasearch
`
`purposes: and
`
`10} the Office of Management and Buciget (OMB) for legislative coordination and clearance.
`
`if you do not furnish the information requested on this form, the USPTO may not he able to process and/or examine
`your submission, which may result in termination of proceedings, abandonment of the application, and/or expiration of
`the patent.
`
`Page 4 of 4
`
`Page 4 of 4
`
`